ECM
QNCX icon

Endurant Capital Management’s Quince Therapeutics QNCX Stock Holding History

Endurant Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-109
Closed -$1.09M – 69
2020
Q3 		$1.09M Buy
+109
New +$991K 0.32% 52

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Endurant Capital Management's QNCX Position: Q4 2020 in Review

Endurant Capital Management sold out of Quince Therapeutics (QNCX) in Q4 2020, closing a stake of 109 shares — an estimated $1.09M sold.

Endurant Capital Management first reported a position in QNCX in Q3 2020 and held it in 1 quarter. The position peaked at $1.09M in Q3 2020. 84 funds tracked by Wall St. Rank hold QNCX as of Q4 2020.

  • Endurant Capital Management reported no remaining Quince Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Endurant Capital Management sold 109 Quince Therapeutics shares in Q4 2020, an estimated $1.09M.
  • Endurant Capital Management first reported a position in Quince Therapeutics in Q3 2020 and held it in 1 quarter.
  • Endurant Capital Management's Quince Therapeutics position peaked at $1.09M in Q3 2020.
  • 84 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2020.

Based on Endurant Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.